Shots:

• Sanofi to acquire Kadmon for $9.50/share in cash making a total equity value of ~ $1.9B with a premium of 79% to a closing price of $5.30 on Sept 07- 2021. The acquisition is expected to be completed in Q4’21
• The acquisition will bolster Sanofi’s transplant business with the addition of Kadmon's Rezurock to treat patients with cGVHD. Sanofi’s transplant business already includes Thymoglobulin & Mozobil that are currently marketed in 65+ countries
• Rezurock is the US FDA approved therapy to treat cGVHD in adult & pediatric patients aged ≥12yrs. who have failed 2 prior lines of systemic therapy & is currently being evaluated in P-II trial for dcSSc

| Ref: Globe Newswire | Image: Medcity News